Clinical Trials · NCT01188733

Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis

Name: Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 1/Phase 2Octreotide

Phase: Phase 1/Phase 2
Recruitment status: Completed
Sponsor: Mayo Clinic
Enrollment: 39
Start date: Jun 1998
Locations: See registry
Primary endpoint: Study in Cirrhosis

View Octreotide compound reference